Acute toxicity of combined photon IMRT and carbon ion boost for intermediate-risk prostate cancer – Acute toxicity of 12C for PC

References

• Kuban DA, Levy LB, Cheung MR, Lee AK, Choi S, Frank S, . Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease? Int J Radiat Oncol Biol Phys 2011;79:1310–7.
   PubMed Web of Science ®Google Scholar
• Zelefsky MJ, Cowen D, Fuks Z, Shike M, Burman C, Jackson A, . Long term tolerance of high dose three-dimensional conformal radiotherapy in patients with localized prostate carcinoma. Cancer 1999;85:2460–8.
   PubMed Web of Science ®Google Scholar
• Zelefsky MJ, Fuks Z, Hunt M, Yamada Y, Marion C, Ling CC, . High-dose intensity modulated radiation therapy for prostate cancer: Early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys 2002;53:1111–6.
   PubMed Web of Science ®Google Scholar
• Cahlon O, Zelefsky MJ, Shippy A, Chan H, Fuks Z, Yamada Y, . Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: Toxicity and biochemical outcomes. Int J Radiat Oncol Biol Phys 2008;71:330–7.
   PubMed Web of Science ®Google Scholar
• Rossi CJ. Conformal proton beam therapy of prostate cancer – update on the Loma Linda University medical center experience. Strahlenther Onkol 1999;175(Suppl 2): 82–4.
   PubMed Web of Science ®Google Scholar
• Zietman AL, Bae K, Slater JD, Shipley WU, Efstathiou JA, Coen JJ, . Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: Long-term results from proton radiation oncology group/American College of Radiology 95-09. J Clin Oncol 2010;28:1106–11.
   PubMed Web of Science ®Google Scholar
• Akakura K, Tsujii H, Morita S, Tsuji H, Yagishita T, Isaka S, . Phase I/II clinical trials of carbon ion therapy for prostate cancer. Prostate 2004;58:252–8.
   PubMed Web of Science ®Google Scholar
• Ishikawa H, Tsuji H, Kamada T, Yanagi T, Mizoe JE, Kanai T, . Carbon ion radiation therapy for prostate cancer: Results of a prospective phase II study. Radiother Oncol 2006;81:57–64.
   PubMed Web of Science ®Google Scholar
• Haberer T, Becher W, Schardt D, Kraft G. Magnetic scanning system for heavy ion therapy. Nucl Instr Meth Phys Res 1993;330:296–305.
   Web of Science ®Google Scholar
• Krämer M, Jäkel O, Haberer T, Rietzel E, Schardt D, Scholz M, . Treatment planning for scanned ion beams. Radiother Oncol 2004;73(Suppl 2):S80–5.
   PubMed Web of Science ®Google Scholar
• Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trial 1989;10:1–10.
   PubMedGoogle Scholar
• Herfarth KK, Pirzkall A, Lohr F, Schulz-Ertner D, Spoo J, Frank C, . First experiences with a noninvasive patient set-up system for radiotherapy of the prostate. Strahlenther Onkol 2000;176:217–22.
   PubMed Web of Science ®Google Scholar
• Kraft G. RBE and its interpretation. Strahlenther Onkol 1999;175(Suppl II):44–7.
   PubMed Web of Science ®Google Scholar
• Preiser K, Bortfeld T, Hartwig K, Schlegel W, Stein J. Inverse radiotherapy planning for intensity modulated photon fields. Radiologe 1998;38:228–34.
   PubMed Web of Science ®Google Scholar
• Abramowitz MC, Li T, Buyyounouski MK, Ross E, Uzzo RG, Pollack A, . The Phoenix definition of biochemical failure predicts for overall survival in patients with prostate cancer. Cancer 2008;112:55–60.
   PubMed Web of Science ®Google Scholar
• Matzinger O, Duclos F, van den Bergh A, Carrie C, Villà S, Kitsios P, . EORTC Radiation Oncology Group. Acute toxicity of curative radiotherapy for intermediate- and high-risk localised prostate cancer in the EORTC trial 22991. Eur J Cancer 2009;45:2825–34.
   PubMed Web of Science ®Google Scholar
• Zelefsky MJ, Levin EJ, Hunt M, Yamada Y, Shippy AM, Jackson A, . Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2008;70:1124–9.
   PubMed Web of Science ®Google Scholar
• Coen JJ, Bae K, Zietman AL, Patel B, Shipley WU, Slater JD, . Acute and late toxicity after dose escalation to 82 GyEGyEGyE using conformal proton radiation for localized prostate cancer: Initial Report of American College of Radiology Phase II Study 03-12. Int J Radiat Oncol Biol Phys Epub 2010 Oct 5.
   Google Scholar
• Fowler J, Chappell R, Ritter M. Is a/ß for prostate tumors really low? Int J Radiat Oncol Biol Phys 2001;50:1021–31.
   PubMed Web of Science ®Google Scholar
• Thames HD, Kuban D, Levy LB, Horwitz EM, Kupelian P, Martinez A, . The role of overall treatment time in the outcome of radiotherapy of prostate cancer: An analysis of biochemical failure in 4839 men treated between 1987 and 1995. Radiother Oncol 2010;96:6–12.
   PubMed Web of Science ®Google Scholar
• Nikoghosyan A, Schulz-Ertner D, Didinger B, Jäkel O, Zuna I, Höss A, . Evaluation of the therapeutical potential of heavy ion therapy for patients with locally advanced prostate cancer. Int J Radiat Oncol Biol Phys 2004;58:89–97.
   PubMed Web of Science ®Google Scholar
• Thörnqvist S, Petersen JB, Høyer M, Bentzen LN, Muren LP. Propagation of target and organ at risk contours in radiotherapy of prostate cancer using deformable image registration. Acta Oncol 2010;49:1023–32.
   PubMed Web of Science ®Google Scholar
• Søvik A, Rødal J, Skogmo HK, Lervåg C, Eilertsen K, Malinen E. Adaptive radiotherapy based on contrast enhanced cone beam CT imaging. Acta Oncol 2010;49: 972–7.
   PubMed Web of Science ®Google Scholar
• Bolla M, de Reijke TM, Van Tienhoven G, Van den Bergh AC, Oddens J, Poortmans PM, . EORTC Radiation Oncology Group and Genito-Urinary Tract Cancer Group. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 2009;360:2516–27.
   PubMed Web of Science ®Google Scholar